218 related articles for article (PubMed ID: 35264575)
1. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.
Kumar H; Mazumder S; Chakravarti S; Sharma N; Mukherjee UK; Kumar S; Baughn LB; Van Ness BG; Mitra AK
Blood Cancer J; 2022 Mar; 12(3):39. PubMed ID: 35264575
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells.
Kumar H; Mazumder S; Sharma N; Chakravarti S; Long MD; Meurice N; Petit J; Liu S; Chesi M; Sanyal S; Stewart AK; Kumar S; Bergsagel L; Rajkumar SV; Baughn LB; Van Ness BG; Mitra AK
Front Oncol; 2022; 12():842200. PubMed ID: 35646666
[TBL] [Abstract][Full Text] [Related]
3. Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer.
Mazumder S; Mitra Ghosh T; Mukherjee UK; Chakravarti S; Amiri F; Waliagha RS; Hemmati F; Mistriotis P; Ahmed S; Elhussin I; Salam AB; Dean-Colomb W; Yates C; Arnold RD; Mitra AK
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497496
[TBL] [Abstract][Full Text] [Related]
4. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma.
Mitra AK; Kumar H; Ramakrishnan V; Chen L; Baughn L; Kumar S; Rajkumar SV; Van Ness BG
Blood Cancer J; 2020 Jul; 10(7):78. PubMed ID: 32724061
[TBL] [Abstract][Full Text] [Related]
5. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Walker ZJ; Idler BM; Davis LN; Stevens BM; VanWyngarden MJ; Ohlstrom D; Bearrows SC; Hammes A; Smith CA; Jordan CT; Mark TM; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2021 Feb; 27(3):819-830. PubMed ID: 33109736
[TBL] [Abstract][Full Text] [Related]
6. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
[TBL] [Abstract][Full Text] [Related]
8. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Le Ray E; Jagannath S; Palumbo A
Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
[TBL] [Abstract][Full Text] [Related]
9. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Gu C; Wang Y; Zhang L; Qiao L; Sun S; Shao M; Tang X; Ding P; Tang C; Cao Y; Zhou Y; Guo M; Wei R; Li N; Xiao Y; Duan J; Yang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):11. PubMed ID: 34991674
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
11. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
[TBL] [Abstract][Full Text] [Related]
12. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
14. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.
Ziccheddu B; Biancon G; Bagnoli F; De Philippis C; Maura F; Rustad EH; Dugo M; Devecchi A; De Cecco L; Sensi M; Terragna C; Martello M; Bagratuni T; Kastritis E; Dimopoulos MA; Cavo M; Carniti C; Montefusco V; Corradini P; Bolli N
Blood Adv; 2020 Mar; 4(5):830-844. PubMed ID: 32126144
[TBL] [Abstract][Full Text] [Related]
16. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
18. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
19. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
